Shanghai - Delayed Quote CNY

InnoCare Pharma Limited (688428.SS)

Compare
13.39 -0.24 (-1.76%)
At close: 3:00:02 PM GMT+8
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 688428.SS

Recent News: 688428.SS

View More

Latest Data of InnoCare’s Orelabrutinib Presented at the 66th Annual Meeting of ASH
Business Wire 7 days ago

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China
Business Wire last month
InnoCare Pharma (SEHK:9969) Achieves Key Milestone with ICP-488 Phase II Success in Psoriasis Treatment

InnoCare Pharma (SEHK:9969) Achieves Key Milestone with ICP-488 Phase II Success in Psoriasis Treatment
Simply Wall St. last month
InnoCare’s Phase II psoriasis therapy trial meets primary endpoint

InnoCare’s Phase II psoriasis therapy trial meets primary endpoint
Clinical Trials Arena 2 months ago

InnoCare Announces Phase II Study Results of TYK2 Inhibitor ICP-488 Meet Primary Endpoint in Psoriasis Patients
Business Wire 2 months ago

InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 for Acute Myeloid Leukemia in China
Business Wire 2 months ago

Latest Data of InnoCare’s Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2024
Business Wire 3 months ago

InnoCare Releases 2024 Interim Results and Business Highlights
Business Wire 3 months ago

British Journal of Cancer: Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumors with on-target resistance to first-generation agents
Business Wire 4 months ago

InnoCare Announces First Subject Dosed in Clinical Trial of TYK2 Inhibitor ICP-332 in the U.S.
Business Wire 4 months ago

InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China
Business Wire 5 months ago
View More

Related Tickers

50BA.SG Bicycle Therapeutics PLC
13.80
+5.34%
 
6996.HK Antengene Corporation Limited
0.610
-4.69%
 
1541.HK IMMUNEONCO-B
6.140
+1.99%
 
2171.HK CARsgen Therapeutics Holdings Limited
9.650
-0.31%
 
CASI CASI Pharmaceuticals, Inc.
3.1300
+0.64%
 
ERNA Eterna Therapeutics Inc.
0.2850
-1.38%
 
IMAB I-Mab
0.9999
-0.01%
 
IPSC Century Therapeutics, Inc.
1.1750
-3.67%
 
APLM Apollomics, Inc.
8.34
+7.76%
 
LEGN Legend Biotech Corporation
34.74
-1.08%